# RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

> **NCT01082146** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Pharmacokinetics
- Metabolism

## Interventions

- **DRUG:** Lurasidone

## Key facts

- **NCT ID:** NCT01082146
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082146, "RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01082146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*